Core Points - Scienture Holdings, Inc. has regained compliance with Nasdaq Listing Rule 5550(a)(2) as its common stock has maintained a closing bid price of $1.00 or greater for the last ten consecutive business days [1][2] - The company was previously notified on May 19, 2025, that it was not in compliance with the minimum bid price requirement and was given a compliance period of 180 calendar days to rectify the situation [2] - The leadership expressed satisfaction with the team's efforts to regain compliance and emphasized the focus on upcoming product launches, particularly the FDA-approved product Arbli [3] Company Overview - Scienture Holdings, Inc. operates as a holding company for pharmaceutical companies, aiming to provide enhanced value through the development and distribution of novel specialty products [1][4] - The company, through its subsidiary Scienture, LLC, is dedicated to addressing unmet market needs across various therapeutic areas and market segments [4]
Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements